The Epidemiology of Chronic Hepatitis C and One-Time Hepatitis C Virus Testing of Persons Born During 1945 to 1965 in the United States

Clinics in Liver Disease

Volumn 17, Issue 1, 2013, Pages 1-11

  Ward, John W ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Baby boomers; HCV testing; HCV testing recommendations; Hepatitis C virus

Indexed keywords

CAUSE OF DEATH; DISEASE TRANSMISSION; ECONOMIC ASPECT; ENVIRONMENTAL EXPOSURE; HEALTH CARE POLICY; HEALTH SURVEY; HEPATITIS C; HEPATITIS C VIRUS TESTING; HUMAN; INCIDENCE; MEDICAL HISTORY; NONHUMAN; PATIENT CARE; PREVALENCE; REVIEW; SEROCONVERSION; SERODIAGNOSIS; UNITED STATES; VIRUS TRANSMISSION;

HEALTH POLICY; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; PREVALENCE; RISK FACTORS; UNITED STATES;

EID: 84869988183     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2012.09.011     Document Type: Review

References (66)

1. Armstrong G.L., Wasley A., Simard E.P., et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006, 144:705-714.
2. Ghany M.G., Strader D.B., Thomas D.L., et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374. [Practice Guideline].
3. Ly K., Xing J., Klevens M., et al. The growing burden of mortality from viral hepatitis in the US, 1999-2007. Ann Intern Med 2012, 156(4):271.
4. Jacobson I., McHutchison J., Dusheiko G., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364(25):2405-2416.
5. Poordad F., McCone J., Bacon B., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364(13):1195-1206.
6. Asselah T., Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int 2012, 32(Suppl 1):S88-S102.
7. Roblin D.W., Smith B.D., Weinbaum C.M., et al. Hepatitis C virus screening practices and prevalence in a managed care organization. Am J Manag Care 2011, 17:548-555.
8. Southern W.N., Drainoni M.L., Smith B.D., et al. Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting. J Viral Hepat 2011, 18:474-481.
9. Spradling P.R., Rupp L., Moorman A.C., et al. Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence. Clin Infect Dis 2012, 55(8):1047-1055.
10. Moorman A.C., Gordon S.C., Rupp L.B., et al. Baseline characteristics and mortality among people in care for chronic viral hepatitis: the Chronic Hepatitis Cohort Study (CHeCS). Clin Infect Dis 2012, [Epub ahead of print].
11. Volk M.L., Tocco R., Saini S., et al. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009, 50:1750-1755.
12. Denniston M.M., Klevens R.M., McQuillan G.M., et al. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008. Hepatology 2012, 55(6):1652-1661.
13. Koretz R.L., Brezina M., Polito A.J., et al. Non-A, non-B posttransfusion hepatitis: comparing C and non-C hepatitis. Hepatology 1993, 17(3):361-365.
14. Marranconi F., Mecenero V., Pellizzer G.P., et al. HCV infection after accidental needlestick injury in health-care workers. Infection 1992, 20(2):111.
15. Seeff L.B. Hepatitis C from a needlestick injury. Ann Intern Med 1991, 115(5):411.
16. Hagan H., Des Jarlais D.C., Stern R., et al. HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection. Int J Drug Policy 2007, 18(5):341-351.
17. Hagan H., Thiede H., Weiss N.S., et al. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 2001, 91(1):42-46.
18. Lucidarme D., Bruandet A., Ilef D., et al. Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France. Epidemiol Infect 2004, 132(4):699-708.
19. Garfein R.S., Vlahov D., Galai N., et al. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996, 86(5):655-661.
20. CDC Prevention and control of infections with hepatitis viruses in correctional settings. MMWR Recomm Rep 2003, 52(RR-01):1-33.
21. Thompson N.D., Perz J.F., Moorman A.C., et al. Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998-2008. Ann Intern Med 2009, 150(1):33-39.
22. Alter M.J. Occupational exposure to hepatitis C virus: a dilemma. Infect Control Hosp Epidemiol 1994, 15(12):742-744.
23. Lanphear B.P., Linnemann C.C., Cannon C.G., et al. Hepatitis C virus infection in healthcare workers: risk of exposure and infection. Infect Control Hosp Epidemiol 1994, 15(12):745-750.
24. Puro V., Petrosillo N., Ippolito G. Risk of hepatitis C seroconversion after occupational exposures in health care workers. Italian study group on occupational risk of HIV and other bloodborne infections. Am J Infect Control 1995, 23(5):273-277.
25. Mitsui T., Iwano K., Masuko K., et al. Hepatitis C virus infection in medical personnel after needlestick accident. Hepatology 1992, 16(5):1109-1114.
26. Scheinmann R., Hagan H., Lelutiu-Weinberger C., et al. Non-injection drug use and hepatitis C virus: a systematic review. Drug Alcohol Depend 2007, 89(1):1-12.
27. Kamili S., Krawczynski K., McCaustland K., et al. Infectivity of hepatitis C virus in plasma after drying and storing at room temperature. Infect Control Hosp Epidemiol 2007, 28(5):519-524.
28. Mast E.E., Hwang L.Y., Seto D.S., et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis 2005, 192(11):1880-1889.
29. Thomas D.L., Villano S.A., Riester K.A., et al. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and infants transmission study. J Infect Dis 1998, 177(6):1480-1488.
30. Alter M.J., Gerety R.J., Smallwood L.A., et al. Sporadic non-A, non-B hepatitis: frequency and epidemiology in an urban U.S. population. J Infect Dis 1982, 145(6):886-893.
31. Williams I.T., Bell B.P., Kuhnert W., et al. Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006. Arch Intern Med 2011, 171(3):242-248.
32. Vandelli C., Renzo F., Romano L., et al. Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study. Am J Gastroenterol 2004, 99(5):855-859.
33. Balogun M.A., Ramsay M.E., Parry J.V., et al. A national survey of genitourinary medicine clinic attenders provides little evidence of sexual transmission of hepatitis C virus infection. Sex Transm Infect 2003, 79(4):301-306.
34. Marincovich B., Castilla J., del Romero J., et al. Absence of hepatitis C virus transmission in a prospective cohort of heterosexual serodiscordant couples. Sex Transm Infect 2003, 79(2):160-162.
35. Terrault N.A. Sexual activity as a risk factor for hepatitis C. Hepatology 2002, 36(5 Suppl 1):S99-S105.
36. Bottieau E., Apers L., Van Esbroeck M., et al. Hepatitis C virus infection in HIV-infected men who have sex with men: sustained rising incidence in Antwerp, Belgium, 2001-2009. Euro Surveill 2010, 15(39):19673.
37. van de Laar T.J., van der Bij A.K., Prins M., et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis 2007, 196(2):230-238.
38. Fox J., Nastouli E., Thomson E., et al. Increasing incidence of acute hepatitis C in individuals diagnosed with primary HIV in the United Kingdom. AIDS 2008, 22(5):666-668.
39. CDC Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men- New York City, 2005-2010. MMWR Recomm Rep 2011, 60(28):945-950.
40. Armstrong G.L., Alter M.J., McQuillan G.M., et al. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000, 31:777-782.
41. Alter M.J. Epidemiology of hepatitis C. Hepatology 1997, 26(Suppl):62S-65S.
42. CDC. Viral hepatitis surveillance, United States, 2009-2011. Available at: Accessed June 18, 2012. http://www.cdc.gov/hepatitis/Statistics/2010Surveillance/index.htm.
43. CDC Hepatitis C virus infection among adolescents and young adults -Massachusetts, 2002-2009. MMWR Recomm Rep 2011, 60(17):537-554.
44. CDC Notes from the field: hepatitis C virus infections among young adults-rural Wisconsin, 2010. MMWR Recomm Rep 2012, 61(19):358.
45. Chak E., Talal A., Sherman K., et al. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011, 31:1090-1101.
46. Kim W.R., Terrault N.A., Pedersen R.A., et al. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology 2009, 137(5):1680-1686.
47. El-Serag H.B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012, 142(6):1264-1273.
48. Simard E.P., Ward E.M., Siegel R., et al. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 2012, 62:118-128.
49. Freeman A.J., Dore G.J., Law M.G., et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001, 34(4 Pt 1):809-816.
50. Hassan M.M., Frome A., Patt Y.Z., et al. Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States. J Clin Gastroenterol 2002, 35(3):266-269.
51. Rein D.B., Wittenborn J.S., Weinbaum C.M., et al. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis 2011, 43(1):66-72.
52. Smith B.D., Patel N., Beckett G.A., et al. Hepatitis C virus antibody prevalence, correlates and predictors among persons born from 1945 through 1965, United States, 1999-2008 2011, [abstract], American Association for the Study of Liver Disease, San Francisco (CA).
53. Kanwal F., Hoang T., Kramer J.R., et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011, 140(4):1182-1188.
54. Su J., Brook R.A., Kleinman N.L., et al. The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs. Hepatology 2010, 52(2):436-442.
55. Davis K.L., Mitra D., Medjedovic J., et al. Direct economic burden of chronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol 2011, 45(2):17-24.
56. Wong J.B., Davis G.L., McHutchison J.G., et al. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol 2003, 98(11):2354-2362.
57. Sullivan S.D., Jensen D.M., Bernstein D.E., et al. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Am J Gastroenterol 2004, 99(8):1490-1496.
58. Lok A.S., Gardiner D.F., Lawitz E. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012, 366(3):216-224.
59. Ghany M., Nelson D., Strader D., et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54(4):1433-1444.
60. IOM (Institute of Medicine) Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C 2010, The National Academies Press, Washington, DC.
61. CDC. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep 1998, 47(RR-19):1-39.
62. CDC Recommendations for the identification of chronic hepatitis C virus (HCV) among persons born during 1945-1965. MMWR Recomm Rep 2012, 61(RR-4):1-32.
63. Rein D.B., Smith B.D., Wittenborn J.S., et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 2012, 156(4):263-270.
64. US Department of Health and Human Services Combating the silent epidemic of viral hepatitis: action plan for the prevention, care, and treatment of viral hepatitis 2011, HHS, Washington, DC, p. 1-76.
65. Arora S., Thornton K., Murata G., et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med 2011, 364(23):2199-2207.
66. Smith B.D., Drobeniuc J., Jewett A., et al. Evaluation of three rapid screening assays for detection of antibodies to hepatitis C virus. J Infect Dis 2011, 204(6):825-831.